Western Sky Medical Research

El Paso, Texas 79932

3 studies enrolling now · 40 studies all time

What they study most

Allergic Rhinitis, Allergy, Allergy, Peanut, Asthma, Atopic Dermatitis, COPD, Chronic Inducible Urticaria, Chronic Spontaneous Urticaria, Chronic Spontaneous Urticaria (CSU), Diabetes Mellitus, Type 2, Lung Diseases, Obstructive, PAR

Studies at this site

• A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines — Recruiting now
• Use of fenoTRACK Device for Monitoring Changes of Fractional Exhaled Nitric Oxide (FeNO) in Uncontrolled Asthma Subjects and Controlled Asthma Subjects — Recruiting now
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria — Enrolling by invitation
• Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) — Running, not enrolling
• Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU) — Completed
• Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts — Completed
• A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines — Running, not enrolling
• Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma — Running, not enrolling
• Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy — Completed
• A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) — Running, not enrolling
• Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma — Stopped early
• An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib — Running, not enrolling
• A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks. — Completed
• A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. — Completed
• Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008) — Completed
• CNP-201 in Subjects With Peanut Allergy — Stopped early
• Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy — Stopped early
• Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients — Completed
• Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) — Completed
• PALISADE Follow-on Study (ARC004) — Completed
• Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) — Completed
• AR101 Real-World Open-Label Extension Study — Completed
• Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis — Completed
• GB001 in Adult Subjects With Moderate to Severe Asthma — Completed
• Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes — Completed
• Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus) — Completed
• A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis — Stopped early
• A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis — Completed
• A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma — Completed
• Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis — Completed
• A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR) — Completed
• A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR). — Completed
• A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies — Completed
• Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray — Completed
• A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older — Completed
• A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis — Completed
• Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma — Completed
• 26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies — Completed
• Safety Study of Zileuton Injection in Patients With Asthma — Completed